‘We Have a Job to Do’: Cancer Patients and Their Doctors Carry on With Clinical Trials During Covid-19

June 17, 2020 5:00 pm

By Elizabeth Cooney

Cancer isn’t waiting for Covid-19 to go away. Neither is Karen Howley.

Diagnosed two years ago with advanced ovarian cancer, Howley started on a new experimental drug in mid-March, just as coronavirus case counts were soaring in … Read more

Berzosertib: Protein-Targeting Drug Used to Treat Cancer May Have Same Effect on Coronavirus

June 16, 2020 7:00 pm

Scientists have begun using berzosertib, a protein-targeting drug, as an accompaniment to chemotherapy for patients with ovarian cancer. The drug is currently in its second phase of trials with cancer patients and is showing promising results for how it … Read more

FDA Approves Pembrolizumab for TMB-High Tumors

June 16, 2020 3:00 am

The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.Read more

Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer

June 3, 2020 5:00 pm

Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020).

In the interim … Read more

Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer

May 30, 2020 5:00 pm

By Susan Moench, PhD, PA-C

This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.

Early results from a single-arm phase 1b study conducted in … Read more

First Study To Report OS Benefit After Secondary Cytoreductive Surgery in Select Patients With Recurrent Ovarian Cancer

May 29, 2020 5:00 pm

By Susan Moench, PhD, PA-C

According to results of a prospective, randomized clinical trial of selected patients with platinum-sensitive, recurrent ovarian cancer assigned to receive second-line platinum-based chemotherapy preceded by secondary cytoreductive surgery versus not, OS was significantly longer for … Read more

Combined Cediranib and Olaparib Presents Similar Activity to Standard of Care Treatment

May 29, 2020 10:00 am

Combined cediranib and olaparib presents similar activity to standard of care treatment for platinum-sensitive ovarian cancer.

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based … Read more

Water-Only Fasting May Reduce Chemo Modifications, Hospital Admissions

April 3, 2020 10:00 am

By Neil Osterweil

FROM SGO 2020

Patients with gynecologic malignancies who consumed only water for 24 hours before and 24 hours after each chemotherapy cycle had fewer dose delays and reductions compared with patients who didn’t fast, results of a

Read more

Barriers to Clinical Trial Participation Revealed By Gynecologic Cancer Patients

March 31, 2020 10:30 am

By Jennifer Smith

A survey of gynecologic cancer survivors has revealed why some of these patients don’t participate in clinical trials.

Half of survey respondents with no history of trial participation said their medical team never mentioned the possibility of
Read more

IMV preps pivotal trials for ovarian cancer T cell therapy

February 26, 2020 11:00 am

IMV says new results from its phase 2 trial of lead drug DPX-Survivac, designed to stimulate a T cell response in ovarian cancer, have set it on course for a registration trial.

The Canadian biotech revealed data from the 22-patient … Read more

IFN-Activated Monocytes Show Early Promise For Ovarian Cancer

February 13, 2020 11:00 am

By Sharon Worcester

REPORTING FROM THE CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM

– Intraperitoneal infusions of peginterferon alfa-2b and interferon gamma-1b, administered with or without autologous monocytes, showed antitumor activity and tolerability in heavily pretreated patients with ovarian cancer in a first-in-human
Read more

Weekly Dose-Dense Chemo Not Recommended in First-Line Epithelial Ovarian Cancer Treatment

December 20, 2019 6:00 pm

By Matthew Fowler

Weekly dose-dense paclitaxel as a frontline treatment for patients with epithelial ovarian cancer was not found to significantly improve progression-free survival (PFS) compared to the standard 3-weekly chemotherapy, according to results from the ICON8 study published in … Read more

Second Surgery for Many Ovarian Cancers Found Ineffective

November 14, 2019 5:00 pm

By Gene Emery

Going back into the operating room for surgery to help a woman whose ovarian cancer has reappeared may not help her live longer – instead, it might shorten her life, according to an international study of 485 … Read more

Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more

PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?

September 29, 2019 6:00 pm

By Ed Susman

PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.

Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more

First-Line Combo Boosts PFS in Advanced Ovarian Cancer

September 28, 2019 5:00 pm

By Charles Bankhead

Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.

Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?

September 20, 2019 8:00 pm

By Dave Levitan

The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more

Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?

August 26, 2019 7:00 pm

By Dave Levitan

The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more